Literature DB >> 2714431

Carboxypeptidase-B-like processing of the C-terminus of glucagon-like peptide-2 in pig and human small intestine.

C Orskov1, T Buhl, L Rabenhøj, H Kofod, J J Holst.   

Abstract

We developed specific, C-terminal radioimmunoassays for three proglucagon (PG) fragments: PG 151-158, PG 151-160 and PG 126-159 (glucagon-like peptide-2 (GLP-2] in order to determine the exact C-terminal sequence of the newly isolated GLP-2 in man and pig. The antigens and the antisera showed no mutual cross-reactivity. By gel filtration of extracts of pig and human small intestine, the immunoreactivity eluting at the position of GLP-2 was identified by the radioimmunoassays for glucagon-like peptide-2 (PG 126-159) and for PG 151-158, whereas the assay for PG 151-160 was completely negative. We conclude that the C-terminal amino acid residue of pig and human ileal GLP-2 is PG 158. Thus the basic residues, PG 159 and 160 are removed during its processing in the small intestine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2714431     DOI: 10.1016/0014-5793(89)81332-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Induction of intestinal epithelial proliferation by glucagon-like peptide 2.

Authors:  D J Drucker; P Erlich; S L Asa; P L Brubaker
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

2.  Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy.

Authors:  J Miholic; C Orskov; J J Holst; J Kotzerke; H J Meyer
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

Review 3.  Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment.

Authors:  Sine Paasch Schiellerup; Kirsa Skov-Jeppesen; Johanne Agerlin Windeløv; Maria Saur Svane; Jens Juul Holst; Bolette Hartmann; Mette Marie Rosenkilde
Journal:  Front Endocrinol (Lausanne)       Date:  2019-02-26       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.